Physicians' Academy for Cardiovascular Education

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

No clinical benefit of potent P2Y12 inhibitor over clopidogrel in peripheral artery disease

Jan. 4, 2017 - AHA 2016, New Orleans, LA, USA - Prof. Freek Verheugt, Amsterdam, The Netherlands

CAC reveals evidence of coronary artery calcification in third of low-risk women

Nov. 14, 2016 - AHA, New Orleans, LA, USA - Dr. Maryam Kavousi, Rotterdam, The Netherlands

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Possible approaches in precision medicine for secundary CV prevention

Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)

A minority of FH patients is identified and labeled as such, which impacts treatment

Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)

Would lower than the current ApoB targets be more useful for clinical decision-making?

Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).

Bisphosphonate as a potential new treatment for CV risk reduction

Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John D Kastelein, MD (AMC Amsterdam, The Netherlands)

Outstanding questions and ongoing studies on the use of NOACs

Oct. 7, 2016 - Berg en Dal, The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA)

Oral anticoagulation in daily clinical practice in varous patient populations

Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)

Understanding why patients do not take their medication and stimulating adherence

Aug. 27, 2016 - ESC Rome, Italy - Prof. Robert Horne (London, United Kingdom)
##SCROLLER_ITEMS_FULL_TITLE##

Lipid-lowering in the elderly - considering net benefit

Nov. 22, 2016 - AHA 2016 - Neil J. Stone, MD (Northwestern University Feinberg School of Medicine, Chicago, IL, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##SCROLLER_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Iron deficiency in the new HF guidelines

Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Extra work of checking device data weekly does not translate into benefit for HF patient

Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK

Amygdalar activity in response to stress predicts development of subsequent CV events

Jan. 19, 2017 - Tawakol A, et al., - The Lancet. 2017.

First study in humans to show a link between activity in the amygdala to subsequent CV events, likely via upregulation of haemopoietic tissue activity and increased atherosclerotic inflammation.

Beneficial effects of antihypertensive therapy on central hemodynamics

Jan. 19, 2017 - Williams B, et al. - Hypertension, 2017

In elderly patients with elevated SBP and pulse pressure, sacubitril/valsartan was superior compared with olmesartan in reducing sitting and ambulatory central aortic and brachial pressures.

Increased platelet reactivity in HIV patients with ACS on dual antiplatelet therapy

Jan. 19, 2017 - Hauguel-Moreau M, et al. - Eur Heart J, 2017

In HIV-ACS patients of the EVERE2ST-HIV study, platelet reactivity and residual platelet reactivity were increased with P2Y12 receptor inhibitors and aspirin, compared to non-HIV ACS patients.

Post-ACS patients are not adequately treated with high-potency statin regimens

Jan. 19, 2017 - Eisen A, et al. - JAHA, 2017

In a large, multinational, post-ACS population, most patients were not treated with high-potency statin regimens early and late after the event which is contradictory to guidelines

High benefit from dual lipid-lowering therapy for ACS patients with a prior CABG

Jan. 18, 2017 - Eisen A, et al. - Eur Heart J, 2017

In an analysis of the IMPROVE-IT study, ACS patients with a history of CABG had a greater clinical benefit of ezetimibe therapy on top of statin versus placebo, compared with patients without CABG.

High SBP and associated morbidity and mortality increased substantially from 1990-2015

Jan. 18, 2017 - news

A global analysis including over 8 million people revealed an increasing rate of SBP above 110 mmHg between 1990 and 2015, which accounts for an estimated 17.8 million deaths in 2015.

Somatostatin concentrations associated with increased risk of CVD and mortality

Jan. 16, 2017 - Abbasi A et al., - Clinical Chemistry 2017

Association between increased plasma NT-proSST concentrations and increased risk of incident CVD and all-cause mortality in those without previous CVD, after adjusting for traditional CVD risk factors.

Agreement to licence two investigational lipid-lowering treatments

Jan. 12, 2017 - news

The agreement is for the development and commercialization of novel treatments for lowering lipoprotein(a) and apolipoprotein C-III

Being active only in the weekends may be sufficient to reduce mortality risk

Association of “Weekend Warrior” and Other Leisure Time Physical Activity Patterns With Risks for All-Cause, Cardiovascular Disease, and Cancer Mortality

Jan. 11, 2017 - O’Donovan G, et al. - JAMA Intern Med, 2017

In a large analysis of 11 population-based cohorts, different physical activity patterns were associated with reduced risks for all-cause-, CVD-, and cancer mortality.

Patients with heterozygous familial hypercholesterolemia benefit from PCSK9-antibody

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo with heterozygous familial hypercholesterolemia

Jan. 11, 2017 - Kastelein JJP, et al. - J Clin Lipidol, 2017

In four studies with patients with heterozygous familial hypercholesterolemia, alirocumab resulted in significant LDL-C-lowering and was well tolerated.

Diabetic HFpEF patients have worse outcomes than non-diabetics

Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients with Heart Failure and Preserved Ejection Fraction. A Report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-Preserve)

Jan. 11, 2017 - Kristensen SL, et al. - Circulation 2017

HFpEF patients with diabetes have worse quality of life, higher NT-proBNP levels, more echocardiographic abnormalities and worse outcomes compared with those without diabetes.

DOACs associated with lower risk of liver injury hospitalisation compared to warfarin

Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation

Jan. 11, 2017 - Alonso A, et al. - Heart. 2017

Dabigatran, rivaroxaban and apixaban users were less often associated with liver injury hospitalisation compared to warfarin and several variables could predict this.

3' education

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

No clinical benefit of potent P2Y12 inhibitor over clopidogrel in peripheral artery disease

Jan. 4, 2017 - AHA 2016, New Orleans, LA, USA - Prof. Freek Verheugt, Amsterdam, The Netherlands

CAC reveals evidence of coronary artery calcification in third of low-risk women

Nov. 14, 2016 - AHA, New Orleans, LA, USA - Dr. Maryam Kavousi, Rotterdam, The Netherlands

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John D Kastelein, MD (AMC Amsterdam, The Netherlands)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Outstanding questions and ongoing studies on the use of NOACs

Oct. 7, 2016 - Berg en Dal, The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA)

Lipid-lowering in the elderly - considering net benefit

Nov. 22, 2016 - AHA 2016 - Neil J. Stone, MD (Northwestern University Feinberg School of Medicine, Chicago, IL, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Iron deficiency in the new HF guidelines

Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Extra work of checking device data weekly does not translate into benefit for HF patient

Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA
##RIGHT_SECTION_ITEMS_FULL_TITLE##

No added value of monitoring platelet function after ACS

Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany

No indication for difference in efficacy between potent platelet inhibitors after PCI

Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark
##RIGHT_SECTION_ITEMS_FULL_TITLE##

CPAP treatment of OSA neutral on CV endpoints but beneficial for quality of life

Oct. 4, 2016 - ESC - 2016 Rome - Prof Doug McEvoy, MD (Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Mendelian randomisation study suggests that CV prevention could be simpler and more effective

Sep. 21, 2016 - ESC - 2016 Rome - Dr. Brian Ference (Detroit, MI, VS)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Heart Failure news from ESC 2016 at a glance

Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

SGLT2 inhibition in diabetic kidney disease

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

New agents to treat hyperkalaemia

July 18, 2016 - ACC 2016 - Bertram Pitt, MD

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom
##RIGHT_SECTION_ITEMS_FULL_TITLE##

HOPE-3 trial suggests that statin therapy is beneficial even in low-risk populations

May 16, 2016 - Dubai, United Arab Emirates - Kausik Ray, MD (Imperial College, London, UK)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Statin lowers CV risk, in absence of LDL-c measurement

Apr. 28, 2016 - ACC 2016, Chicago - Jackie Bosch (Hamilton, ONT, Canada)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

New 2016 ESC Heart Failure Guidelines

May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors (Groningen, The Netherlands)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

May 10, 2016 - David Fitchett, MD, University of Toronto, Canad
##RIGHT_SECTION_ITEMS_FULL_TITLE##

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands

Review of cardiovascular safety of DPP4 inhibitors

May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Stroke reduction with PPAR-Y antagonist pioglitazone

May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
##RIGHT_SECTION_ITEMS_FULL_TITLE##

No benefit of direct renin inhibition in HF in ATMOSPHERE trial

Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Lars Køber
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Recommendations on novel treatments should be composed sooner after publication of evidence

Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Milton Packer
##RIGHT_SECTION_ITEMS_FULL_TITLE##

CV benefit of daily statin therapy in the HOPE-3 trial

Apr. 18, 2016 - ACC 2016, Chicago, IL, USA - Jackie Bosch
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Attenuating inflammation by inhibition of p38 MAP-kinase does not reduce CV endpoints in LATITUDE TIMI-60

Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Michelle O'Donoghue
##RIGHT_SECTION_ITEMS_FULL_TITLE##

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##RIGHT_SECTION_ITEMS_FULL_TITLE##

HOPE-3: Statin therapy works in everybody with intermediate-risk

Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##RIGHT_SECTION_ITEMS_FULL_TITLE##

ACCELERATE: No reduction of major CV events with CETP inhibition

Apr. 7, 2016 - ACC, Chicago 2016 - Stephen J. Nicholls, MD, PhD
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Recent advances in lowering CV risk with antidiabetic agents

Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Inflammation and CV risk: Beyond statins in the treatment of atherosclerosis

Mar. 8, 2016 - Boston, MA, USA - Paul M Ridker
##RIGHT_SECTION_ITEMS_FULL_TITLE##

NOACs for Valve Disease?

Feb. 26, 2016 - VBWG Orlando - John Camm, London, UK
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##RIGHT_SECTION_ITEMS_FULL_TITLE##

CV outcomes with medicines to control glycemia: highlights from recently completed trials

Feb. 2, 2016 - VBWG, Orlando - Darren K. McGuire, MD
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Integrating Big Data with evidence generation for precision medicine: implications for cardiovascular disease

Nov. 7, 2015 - VBWG, Orlando FL, USA - Elliott M. Antman
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Living with heart failure: A patient perspective

Oct. 30, 2015 - HF Summit, Barcelona, Spain - Nick Hartshorne-Evans
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Diagnosing Heart Failure: How, where and who?

Oct. 31, 2015 - HF Summit, Barcelona, Spain - Prof. Burkert Pieske
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Where are we with HF patients with AF?

Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Dipak Kotecha
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Novel insights and innovations in targeting the neurohumoral system

Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Peter van der Meer
##RIGHT_SECTION_ITEMS_FULL_TITLE##

A global overview of key developments in Heart Failure: Where are we now?

Oct. 30, 2015 - HF Summit, Barcelona, Spain - Dr. Kenneth Dickstein
##RIGHT_SECTION_ITEMS_FULL_TITLE##

How to classify your HF patients? Understanding HFpEF versus HFrEF

Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Carolyn Lam
##RIGHT_SECTION_ITEMS_FULL_TITLE##

10' education

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Possible approaches in precision medicine for secundary CV prevention

Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)

A minority of FH patients is identified and labeled as such, which impacts treatment

Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)

Would lower than the current ApoB targets be more useful for clinical decision-making?

Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).

Bisphosphonate as a potential new treatment for CV risk reduction

Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)

Oral anticoagulation in daily clinical practice in varous patient populations

Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)

Understanding why patients do not take their medication and stimulating adherence

Aug. 27, 2016 - ESC Rome, Italy - Prof. Robert Horne (London, United Kingdom)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

Interim results of new device for treatment resistant hypertension

Aug. 29, 2016 - ESC Rome, Italy - Dr. Wilko Spiering (Utrecht, The Netherlands)

Targeting residual inflammatory risk as a strategy to lower CV risk

Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)

Heart failure news at the ESC

Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland
##RIGHT_SECTION_ITEMS_FULL_TITLE##

To SPRINT or not to SPRINT to a lower blood pressure target?

Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Beyond statins: The role of ezetimibe in targeting residual risk

Aug. 29, 2016 - ESC 2016, Rome - Chris Packard, MD – University of Glasgow, United Kingdom

Inflammation as potential target for therapy to target residual risk post ACS

Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Surviving elevated Lp(a): a patient story from diagnosis to treatment

May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

A patient with elevated Lp(a): What is current clinical practice to manage this condition?

May 27, 2016 - Innsbruck, Germany - Prof. Klaus G. Parhofer, MD - University of Munich, Germany - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

The future perspectives for care for patients with high Lp(a)

May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

HF & Diabetes: SGLT2 inhibition a paradigm shift?

Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016

BET inhibition in cardiovascular disease: A new dawn?

Aug. 28, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands - Recorded at PACE-CME symposium at ESC 2016

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

The spectrum of Heart Failure

May 11, 2016 - Boston, MA, USA - Dr. Marc Pfeffer
##RIGHT_SECTION_ITEMS_FULL_TITLE##

What surprises have emerged from genetic studies of coronary artery disease?

Apr. 25, 2016 - Boston, MA, USA - Dr. Sekar Kathiresan (Boston, MA, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Diabetic dyslipidaemia and residual risk in the era of LDL control

Mar. 21, 2016 - Boston, MA, USA - Aruna Pradhan
##RIGHT_SECTION_ITEMS_FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Changing views on mechanisms of atherosclerosis

Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

HF Summit : innovation in clinical care in heart failure

Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie
##RIGHT_SECTION_ITEMS_FULL_TITLE##

A multidisciplinary approach in heart failure management

Oct. 31, 2015 - Barcelona, Spain - Aldo Maggioni, TIny Jaarsma, Richard Hobbs and Josep Comin-Colet
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##RIGHT_SECTION_ITEMS_FULL_TITLE##

SGLT2 inhibitor outcome trials: Future opportunities

Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
##RIGHT_SECTION_ITEMS_FULL_TITLE##

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

Sep. 29, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

What is the story about Diabetes & CVD: Rationale for a multifactorial approach

Sep. 29, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Diabetes & Cardiovascular Disease:The risk factor to be challenged

Sep. 27, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

Sep. 24, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

Sep. 29, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Inflammation in Acute Myocardial Infarction & Ventricular Remodelling

Oct. 21, 2015 - ESC 2015, London UK at Monday, August 31, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##